Investment Thesis
Abeona Therapeutics exhibits severe operational distress with massive operating losses (-$89.4M) and negative free cash flow (-$84.3M) that cannot be sustained despite positive net income driven by non-cash items. The company's profitability metrics are distorted by one-time gains, while underlying cash generation remains deeply negative, indicating fundamental business model challenges in pharmaceutical development.
ABEO Strengths
- Strong liquidity position with $78.4M cash and 6.93x current ratio provides runway for operations
- Low leverage with 0.13x debt-to-equity ratio limits financial distress risk
- Revenue growth of 66.3% YoY shows commercialization progress in pharmaceutical pipeline
ABEO Risks
- Operating losses of -$89.4M with -1536.9% operating margin indicate core business is unprofitable and not scalable
- Negative free cash flow of -$84.3M with current cash burn rate exhausts $78.4M in roughly 10 months without additional financing
- Positive net income of $71.2M contradicts negative operating cash flow, suggesting earnings quality issues driven by non-cash gains or one-time items rather than sustainable operations
- High insider form 4 filing activity (23 in 90 days) may indicate insider concern or active restructuring
Key Metrics to Watch
- Operating cash flow trend and path to cash flow breakeven
- Revenue growth sustainability and gross margin expansion as pipeline matures
- Cash runway and timeline to profitability or next financing requirement
ABEO Financial Metrics
Revenue
$5.8M
Net Income
$71.2M
EPS (Diluted)
$1.01
Free Cash Flow
$-84.3M
Total Assets
$219.6M
Cash Position
$78.4M
ABEO Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,536.9%
Net Margin
1,223.1%
ROE
44.7%
ROA
32.4%
FCF Margin
-1,448.5%
ABEO Balance Sheet & Liquidity
Current Ratio
6.93x
Quick Ratio
6.74x
Debt/Equity
0.13x
Debt/Assets
27.5%
Interest Coverage
-23.92x
Long-term Debt
$20.0M
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 18, 2026 |
Data as of: 2025-12-31 |
Powered by Claude AI